Expression Level and Clinical Significance of VEGF, IL-17, β2-MG and IL-35 in Patients with Multiple Myeloma

Abstract

To explore the expression and clinical significance of VEGF, IL-17, β2-MG and IL-35 in patients with multiple myeloma. A total of 83 patients with multiple myeloma (MM) from January 2012 to December 2016 were enrolled in MM group, 36 healthy subjects were enrolled in control group. The levels of IL-17, IL-35 and VEGF in serum were detected by ELISA. The levels of β2-MG in serum were measured by radioimmunoassay. The differences of different indexes between 2 groups were compared. The serum levels of IL-17, VEGF and β2-MG in serum of III stage were higher than that in II stage, which was higher than that in I stage and control group (P<0.05). The levels of IL-35 in the control group were significantly higher than those in the I,II,III stage group (P<0.05). The levels of IL-17, VEGF and β2-MG in serum of progress period were higher than those in stable phase and control group, level of IL-35 in serum of control group was significantly higher than that in the stable phase and progress period group (P<0.05). The correlation analysis showed that the level of serum IL-17 positively correlated with VEGF, β2-MG expression (r=0.65, 0.58, P<0.05); and the serum IL-17 levels were negatively correlated with IL-35 levels (r=-0.42, P<0.05). The anomalous levels of IL-17, IL-35, IVEGF and β2-MG expressions correlate with the progression and prognosis of patients with multiple myeloma.